Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Votrient (pazopanib hydrochloride)
pCPA File Number:
20902
Negotiation Status:
Concluded with an LOI
Indication(s):
Metastatic Renal Cell Carcinoma
Sponsor/Manufacturer:
GlaxoSmithKline
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2017-03-31
Negotiation Process Concluded:
2017-07-03